EVG Tag

Evgen Pharma PLC – EVG – Final Results

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its final results for the year ended 31 March...

Read More

Evgen Pharma PLC – Half-year Report

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months...

Read More

Evgen Pharma PLC – Update on SAS study

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that the last study visit for the last patient entered in...

Read More

Evgen Pharma PLC – AGM Statement

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting ("AGM") later today. At the...

Read More

Evgen Pharma PLC – Full Year Results

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its final results for the year ended 31 March...

Read More

Evgen Pharma PLC – Interim Results

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on cancer and neurological conditions, announces its unaudited interim results for the six months ended 30 September 2018....

Read More

Evgen Pharma PLC – Full Year Results

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its final results for the year ended 31 March...

Read More